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Plasminogen activators (PA) have been postulated to play a
role in tumour invasion due to their regulatory function in
fibrinolysis and degradation of extracellular matrix compon-
ents (Tanaka et al., 1977; Cajot et al., 1989). PA-mediated
degradation is modulated by their specific inhibitors (Laiho
& Keski-Oja, 1989), urokinase (u-PA) receptors at the cell
surface (Vassalli et al., 1985; Plow et al., 1986) and hormones
and growth factors of the extracellular milieu (Laiho &
Keski-Oja, 1989). Epidermal growth factor (EGF) stimulates
u-PA production (Grimaldi et al., 1986; Niedbala & Sarto-
relli, 1989) whereas changes in the PA system induced by
transforming growth factor-P (TGF-3) differ depending on
the cell type studied. TGF-P enhances secretion of plasmin-
ogen activator inhibitor 1 (PAI-1) and u-PA of the human
adenocarcinoma cell line A549 (Keski-Oja et al., 1988) or
decreases secretion of u-PA and tissue-type PA (t-PA) of
embryonic fibroblasts (Lund et al., 1987). In addition, TGF-P
has been reported to have regulatory functions which
counteract or modulate EGF responses (Keski-Oja et al.,
1987; Sporn et al., 1987). Since these growth factors are
potentially able to control the PA system with regard to its
possible function in invasive growth of tumour cells we inves-
tigated the regulation of u-PA, t-PA and PAI secretion by
EGF, TGF-a and TGF-,B in malignant human lung carcin-
omas. Human lung tumours can be divided into non small
cell lung carcinomas (NSCLC) and small cell lung carcin-
omas (SCLC) by their different clinical and physiological
characteristics. The majority of NSCLC are squamous car-
cinomas, adenocarcinomas and large cell carcinomas. We
used several human NSCLC cell lines which were of squa-
mous cell origin (EPLC-65H, EPLC-272H, U-7152) and of
large cell origin (LCLC-103H, LCLC-97TM1, U-1810). Some
of these cell lines have previously been shown to produce and
secrete components of the PA system, activators as well as
inactivators, in different combinations and amounts (Heidt-
mann et al., 1989). The cell lines have been described to
express receptors for EGF (Haeder et al., 1988) which also
bind TGF-a. For stimulation experiments, the cells were
cultivated in the presence of EGF, TGF-a, TGF-1 or com-
binations of these factors as indicated in Figures 1 and 2. In
addition we treated the cells with PMA which was shown to
stimulate their synthesis of PA components (Heidtmann et
al., 1989). Secreted PA products were detected and resolved
by their molecular mass using fibrin autography (Granelli-
Piperno & Reich, 1978, Figure 1). Briefly, after separation of
serum-free conditioned media in 8% SDS-gels, SDS was
replaced by a non-ionic detergent, and proteins were allowed
to diffuse into an indicator gel of 1% agarose, containing
plasminogen and fibrin. Presence of PA-activity causes lysis
zones in the detection gel. Overall PA activity was deter-
mined by a chromogenic assay (Figure 2).
According to the secretion of u-PA, t-PA and the forma-
tion of PAI-complexes and alterations in their concentrations
as a result of growth factor treatment, several principal pat-
terns of PA constituents could be distinguished in the cell
lines studied. All cell lines were able to produce u-PA. As
judged from the intensity of the u-PA bands, growth factors
influenced its activity only marginally or not at all. As an
exception, cell line EPLC-65H which produced u-PA, t-PA
and PAI at the detection limit showed marked u-PA secre-
tion only after stimulation by growth factors or PMA. Signi-
ficant effects of growth factors were observed in the secretion
of t-PA and the formation of PAI-complexes. Cell lines
EPLC-65H, EPLC-272H, U-1810 were able to produce t-PA
and PAI. In these cell lines, t-PA secretion was either
enhanced by EGF, TGF-a, PMA (EPLC-65H), or t-PA was
already expressed endogenously with no apparent further
increase under the influence of these agents (EPLC-272H and
U-1810). Treatment with TGF-P alone or in combination
with the other factors resulted in weaker expression of the
t-PA band. On the other hand, TGF-P stimulated the forma-
tion of PAI-complexes as demonstrated for cell lines EPLC-
272H and U-1810. The reduced amount of free t-PA under
the influence of TGF-P may be due to two different mechan-
isms: either decreased secretion of t-PA as in cell line EPLC
65H, where the disappearance of t-PA is not accompanied by
increased strength in PAI-complexes, or by complex forma-
tion of t-PA with additionally secreted PAI leading to
stronger PAI-complex bands as in cell lines EPLC-272H and
U-1810. The induction of PAI-complex bands in cell lines
U-1752 and LCLC 103H under EGF, TGF-a and PMA,
which was even more enhanced in the presence of TGF-P,
indicates an increased turnover of PA, even though no t-PA
bands appear, and u-PA bands are apparently not decreased
in strength. Further, the total PA activity (Figure 2) is not
decreased either but, in cell line LCLC-103H, appears to be
increased in the presence of TGF-P instead. Thus it is con-
ceivable, that in these cell lines under TGF-13, PA secretion is
induced, but balanced by PAI. The induction of PA may
either affect t-PA, which is then completely scavenged by
PAI, or u-PA, which is then balanced to different degrees by
concomitantly increased PAI. The cell lines differed in their
PAI-complexes with regard to the band position and inten-
sity in zymography after treatment with the respective
factors. The microheterogeneity of upper and lower PAI-
complex bands after TGF-P treatment, as observed with cell
line EPLC-272H, may be caused by a different glycosylation
of PAI. Although the nature of the PAI responsible for
complexing could not be defined in these experiments, we
presume that the cell lines predominantly produce PAI-I
since EPLC-65H and LCLC-103H were earlier found to
synthesise PAI-1, and LCLC-103H additionally PAI-2 in
small amounts (Heidtmann et al., 1989).
The quantitative assessment of total PA activity (Figure 2)
did not in all cases parallel the impressions gained from the
fibrin autographies. It must be kept in mind that fibrin
autography is, of course, a semiquantitative device. Thus, the
over 3-fold increase in total PA activity in U-1752 under
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Figure 1 Fibrin autography of culture supernatants from human lung cancer cell lines. Zymographic detection ofu-PA, t-PA and
PAI-complexes was carried out as a modification of the method described by Granelli-Piperno and Reich, 1978. Samples were
separated on slabs of 10% SDS-PAGE which were then placed on indicator gels containing 0.22 g agarose (agar noble, Difco, USA), 10 mg fibrinogen, 0.6 U thrombin and 0.8 mg plasminogen (all purchased from Behring Werke, Germany) in a total volume
of 22 ml PBS. Standards consisted of u-PA (50 and 30kDA) and t-PA (60kDA) (Berhring Werke). The t-PA standard contained a
trace contamination of u-PA. Sample sizes were adjusted to give optimal resolution, semiquantitative comparisons are thus only possible for samples of identical cell lines. Fibrin autography was incubated for 3 h. Prior to zymography cells were cultivated in
serum-free RPMI 1640 containing 1% BSA for 2 days untreated (1) or treated with EGF (2), EGF/TGF-P (3), TGF-x (4), TGF-m/TGF-P(5), PMA (6), PMA/TGF-P(7) and TGF-P(8). Growth factors and PMA were applied in concentrations assessed to be optimal in dose/response experiments using the chromogenic assay as described in Figure 2: PMA (5 x 10-9 M), EGF and TGF-a(25 ngml-'), TGF-P(1Ongml-'). PMA and EGF (purified from submaxillary gland of the mouse) were purchased from Sigma (USA); synthetic TGF-a from Bachem, USA; human platelet TGF-P1 from R + D Systemic Inc., USA. Growth factor/PMA treatment did not affect viability of the cells as determined by trypan blue exclusion. Supernatants were separated from cells by centrifugation at 400g. In order to free the supernatants from cellular debris, culture media were centrifuged at 10,000g for 20 min and the supernatants thereof were further used both for zymography and chromogenic assay.
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Figure 2 Plasminogen activator activity in culture supernatants of human lung cancer cell lines. PA activity was determined in
supernatants of the cell lines under the influence of growth factors and PMA. Treatment was as described in Figure 1. Untreated cell cultures (1), treatment with EGF (2), EGF/TGF-P(3), TGF-a (4), TGF-a/TGF-P (5), PMA (6), PMA/TGF-P(7), TGF-P(8). The chromogenic assay was a modification of the assay supplied by Kabi, Sweden (COA-SET):2-100 l of culture supernatant
were brought to 100 LI with 0.05 M Tris-buffer containing 0.01% (v/v) Tween 20, pH 8.3 in microtiter plates, 0.15 ml of a mixture containing plasminogen (Behring Werke), substrate S-2251 (Kabi), and fibrinogen split products (Behring Werke) were added. Mock treatment with PMA or growth factors had no effect on the assay. For control, parallel assays were performed without plasminogen. Absorbance at 410 nm was measured after 75 minat 37'C in an automatic plate reader (Titertek Flow, Germany) and extrapolated to arbitrary units. Columns represent the mean values of triplicate measurements, bars represent SD, Represen- tative values are shown out of a series of three independent experiments.
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PMA (lane 6) is not directly evident from the respective u-PA
band in Figure 1. In cell line EPLC-103H, the addition of
TGF-P together with EGF, TGF-a or PMA led to increased
total PA activity in spite of stronger inhibitor bands, indi-
cating that a complementary increase in PA, either u-PA or
t-PA, must have taken place. Thus, the action of TGF-P
appears to involve the whole system and not only the inhibi-
tory branch. We suggest that growth factors EGF, TGF-a
and TGF-P modulate secretion of t-PA and PAI in these cell
lines which are able to produce both PA's and PAI. Cell lines
U-1752 and LCLC-103H are characterised by a deficiency in
the production of t-PA. No significant effects of growth
factors could be observed with these cell lines. In case of cell
line LCLC-103H it seemed as if TGF-P even enhanced PA
activity. These results support our notion that growth factors
EGF, TGF-x and TGF-P primarily affect regulation of t-PA
and PAI in a combined fashion. The mechanism underlying
this regulation needs to be elucidated. LCLC-97TM1 cells,
deficient in the production of PAI, showed no modulation of
u-PA and t-PA secretion by the growth factors.
The patterns of the PA system and its regulation could not
be correlated to the histological typing or grading of the
original tumours which were squamous cell and large cell
carcinomas of various degree of differentiation (Bepler et al.,
1988; Bergh et al., 1981; Bergh et al., 1985). In a previous
study we had characterised a panel of NSCLC cell lines,
comprising five of the cell lines used here, for their in vitro
differentiation capacity and had found that PMA enhances
the expression of several cellular differentiation markers
(Salge et al., 1990). EGF does not elicit all the responses seen
under PMA, however, similar patterns of response of the PA
system in these cell lines suggest that the induction of the PA
system in NSCLC concurs with states of enhanced cellular
differentiation.
In summary we presume that the expression of a complex
pattern of PA and PAI, modified by EGF/TGF-a and TGF-
P, may represent a general feature of NSCLC. Thus, the cells
have an intricate and finely tuned set of tools for controlled
proteolysis in their extracellular environment which includes
mechanisms like fibrinolysis, tissue remodeling and facilita-
tion of cell migration. Impairments may occur where proteo-
lytic activity prevails over inhibitory activity. This would
entail disturbance of the inhibitory balance leading to un-
controlled proteolysis. We cannot decide at the moment
whether the dysregulations shown here for the cell lines
represent true features of NSCLC or are phenomena acquir-
ed in cell culture. In vivo investigations of fresh tumour tissue
samples may be complicated by the presence of a variety of
non-tumour cells producing proteinases, inhibitors and
growth factors. Therefore, cell culture experiments concern-
ing the regulation of the PA system appear to be indispens-
able.
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